Table 2.
Other targeted or cytotoxic chemotherapy that are used in combination with mTOR inhibitors.
| Drug | Target | References |
|---|---|---|
| RTK inhibitors | ||
| Trastuzumab | HER2 | [244,245] |
| Neratinib | HER2 | [246] |
| Tivantinib | c-Met | [247] |
| Cetuximab | EGFR | [248,249] |
| Bevacizumab | VEGF | [249,250] |
| Dalotuzumab | IGF-1R | [251] |
| Cixutumumab | IGF-1R | [252] |
| Pazopanib | Tyrosine Kinase | [164] |
| Lapatinib | HER2/EGFR | [253] |
| Ras/MAPK Pathway Inhibitors | ||
| Sorafenib | Raf/VEGFR | [228,254,255,256] |
| RAF265 | Pan-Raf | [257] |
| Selumetinib | MEK1/2 | [258,259] |
| MNKI-57; MNKI-4 | Mnk1/2, Mnk2 | [260] |
| Trametinib (GSK1120212) | MEK | [229,261] |
| Pimasertib | MEK | [262,263] |
| Cytotoxic Chemotherapy | ||
| Carboplatin | DNA | [264,265,266] |
| Paclitaxel | Microtubules | [266,267,268] |
| Cisplatin | DNA | [268,269] |
| Vinorelbine | Microtubules | [244,270] |
| Cyclophosphamide | DNA | [271] |
| Doxorubicin | Topoisomerase | [272] |
| Vincristine | Microtubules | [273] |
| Docetaxel | Microtubules | [274] |
| Temozolomide | DNA | [275] |
| Oxaliplatin | DNA | [276] |
| Other Targeted Therapies | ||
| Exemestane | Aromatase | [277] |
| Letrozole | Aromatase | [278] |
| Fulvestrant | Estrogen Receptor | [279] |